AstraZeneca Settles Antitrust Allegations for $51.4 Million Over Seroquel XR Delay

Pieter Gunst01 mins

AstraZeneca Pharmaceuticals LP, in conjunction with Handa Pharmaceuticals LLC, has reached a settlement agreement to pay a total of $51.4 million. This settlement addresses allegations concerning AstraZeneca’s actions of compensating generic-drug makers, including Handa, to prevent market entry of competing generic versions of its brand-name antipsychotic drug, Seroquel XR. This case was resolved with a filing in Delaware federal court, marking an end to the legal disputes surrounding AstraZeneca’s practices. For further details, the complete report can be accessed here.